Cardiol Therapeutics Inc. Class A Common Shares CRDL · Stock Open Cardiol Therapeutics Inc. Class A Common Shares in new tab
Cardiol Therapeutics Inc. Class A Common Shares Analysis (CRDL)
Is Cardiol Therapeutics Inc. Class A Common Shares a good investment? Cardiol Therapeutics Inc. Class A Common Shares (CRDL) is currently trading at 1.56 USD. Market analysts have a consensus price target of 8.39 USD. This suggests a potential upside from current levels.
Earnings Schedule: Cardiol Therapeutics Inc. Class A Common Shares is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.23.
Investor FAQ
Does Cardiol Therapeutics Inc. Class A Common Shares pay a dividend?
No, it does not currently pay a dividend.
What asset class is Cardiol Therapeutics Inc. Class A Common Shares?
Cardiol Therapeutics Inc. Class A Common Shares is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -0.24.
Company Profile
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Community Discussion